ANNX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.318

-3.64%

-0.340

-8.11%

-0.340

-0%

Estimates Revision

The market is revising No Change the revenue expectations for Annexon, Inc. (ANNX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 81.32%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.06%

In Past 3 Month

Stock Price

Go Up

+81.32%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast ANNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANNX is 14.00 USD with a low forecast of 8.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.805

Low

8.00

Averages

14.00

High

27.00

Current: 4.805

Low

8.00

Averages

14.00

High

27.00

Wells Fargo

NULL

Overweight

upgrade

$14 -> $27

2025-11-19

Reason

Wells Fargo

Price Target

$14 -> $27

2025-11-19

upgrade

NULL

Overweight

Reason

Wells Fargo raised the firm's price target on Annexon to $27 from $14 and keeps an Overweight rating on the shares. The firm is raising its probability of success to 55% from 10% that vonaprument's Phase 3 trial in GA will be positive in the second half of 2026. Wells believes the setup offers a significant, asymmetric risk/reward skew with the potential for VC-like upside in the next 12 months.

BofA

Buy

downgrade

$9 -> $8

2025-11-16

Reason

BofA

Price Target

$9 -> $8

2025-11-16

downgrade

Buy

Reason

BofA lowered the firm's price target on Annexon to $8 from $9 and keeps a Buy rating on the shares. The firm updated smid-cap biotech models following the Q3 reports.

Wells Fargo

Derek Archila

Overweight

maintain

$14

2025-07-10

Reason

Wells Fargo

Derek Archila

Price Target

$14

2025-07-10

maintain

Overweight

Reason

Wells Fargo analyst Derek Archila spoke to Annexon as the shares traded down earlier today post the circulation of a tweet from a month ago by a physician. A doctor claimed the FDA requested a confirmatory study of tanruprubart in the U.S. as it did not accept the comparison to the International GBS Outcomes Study database as evidence of efficacy in western Guillain-Barre syndrome, the analyst tells investors in a research note. Wells spoke to management, who said the post is not factual. Annexon's CEO noted this post was one week before the company's FDA meeting, Wells points out. The company told the firm that the FDA has not requested another confirmatory trial. After selling off earlier in the day, shares of Annexon are up 2% to $2.82 in afternoon trading. Wells keeps an Overweight rating on the shares with a $14 price target. It recommends buying the shares on weakness.

H.C. Wainwright

Buy

downgrade

$20 -> $14

2025-05-13

Reason

H.C. Wainwright

Price Target

$20 -> $14

2025-05-13

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Annexon to $14 from $20 and keeps a Buy rating on the shares. The firm reduced the stock's multiple and increased its discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk. Annexon announced that it is on track to meet with the FDA for tanruprubart around Q2, the analyst tells investors in a research note.

Needham

Joseph Stringer

Strong Buy

Reiterates

$16

2025-03-04

Reason

Needham

Joseph Stringer

Price Target

$16

2025-03-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$30

2024-12-17

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$30

2024-12-17

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Annexon Inc (ANNX.O) is -3.76, compared to its 5-year average forward P/E of -3.66. For a more detailed relative valuation and DCF analysis to assess Annexon Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.66

Current PE

-3.76

Overvalued PE

-1.23

Undervalued PE

-6.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.33

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.46

Undervalued EV/EBITDA

-3.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.05

Current PS

0.00

Overvalued PS

1.90

Undervalued PS

-1.79

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ANNX News & Events

Events Timeline

No data

News

5.0

11-20Yahoo Finance

Annexon Stock Soars Following Director's $5.06 Million Share Acquisition

5.0

11-20NASDAQ.COM

Insider Buying Update for Thursday, November 20: ANNX, TH

4.0

11-19Benzinga

Wells Fargo Keeps Overweight Rating on Annexon and Increases Price Target to $27

People Also Watch

Frequently Asked Questions

What is Annexon Inc (ANNX) stock price today?

The current price of ANNX is 4.805 USD — it has decreased -2.14 % in the last trading day.

What is Annexon Inc (ANNX)'s business?

Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

What is the price predicton of ANNX Stock?

What is Annexon Inc (ANNX)'s revenue for the last quarter?

Annexon Inc revenue for the last quarter amounts to -57.02M USD, increased 44.56 % YoY.

What is Annexon Inc (ANNX)'s earnings per share (EPS) for the last quarter?

Annexon Inc. EPS for the last quarter amounts to -52352000.00 USD, increased 63.48 % YoY.

What changes have occurred in the market's expectations for Annexon Inc (ANNX)'s fundamentals?

How many employees does Annexon Inc (ANNX). have?

Annexon Inc (ANNX) has 100 emplpoyees as of December 16 2025.

What is Annexon Inc (ANNX) market cap?

Today ANNX has the market capitalization of 731.86M USD.